A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
NCT ID: NCT01178125
Last Updated: 2021-11-09
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
2858 participants
INTERVENTIONAL
2010-08-31
2013-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DR-102
desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
DR-102
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DR-102
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agreement to use study oral contraceptive therapy as their only method of birth control during the study
* History of regular spontaneous menstrual cycles or withdrawal bleeding episodes
* Others as dictated by protocol
Exclusion Criteria
* Pregnancy or plans to become pregnant in the next 14 months
* Smoker and age greater than or equal to 35 years
* Others as dictated by protocol
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teva Women's Health Research Protocol Chair
Role: STUDY_CHAIR
Teva Women's Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Teva Investigational Site 10007
Montgomery, Alabama, United States
Teva Investigational Site 10013
Phoenix, Arizona, United States
Teva Investigational Site 10017
Phoenix, Arizona, United States
Teva Investigational Site 10032
Little Rock, Arkansas, United States
Teva Investigational Site 10026
San Diego, California, United States
Teva Investigational Site 10056
San Diego, California, United States
Teva Investigational Site 10002
Colorado Springs, Colorado, United States
Teva Investigational Site 10033
Colorado Springs, Colorado, United States
Teva Investigational Site 10057
Washington D.C., District of Columbia, United States
Teva Investigational Site 10052
Clearwater, Florida, United States
Teva Investigational Site 10021
Jacksonville, Florida, United States
Teva Investigational Site 10036
Leesburg, Florida, United States
Teva Investigational Site 10012
Miami, Florida, United States
Teva Investigational Site 10015
Miami, Florida, United States
Teva Investigational Site 10055
Palm Beach Gardens, Florida, United States
Teva Investigational Site 10001
West Palm Beach, Florida, United States
Teva Investigational Site 10031
Decatur, Georgia, United States
Teva Investigational Site 10041
Roswell, Georgia, United States
Teva Investigational Site 10050
Savannah, Georgia, United States
Teva Investigational Site 10008
Louisville, Kentucky, United States
Teva Investigational Site 10023
Mount Sterling, Kentucky, United States
Teva Investigational Site 10048
Lawrenceville, New Jersey, United States
Teva Investigational Site 10030
Moorestown, New Jersey, United States
Teva Investigational Site 10014
Albuquerque, New Mexico, United States
Teva Investigational Site 10006
Rochester, New York, United States
Teva Investigational Site 10044
Cary, North Carolina, United States
Teva Investigational Site 10040
Charlotte, North Carolina, United States
Teva Investigational Site 10034
New Bern, North Carolina, United States
Teva Investigational Site 10018
Winston-Salem, North Carolina, United States
Teva Investigational Site 10046
Winston-Salem, North Carolina, United States
Teva Investigational Site 10022
Columbus, Ohio, United States
Teva Investigational Site 10039
Columbus, Ohio, United States
Teva Investigational Site 10028
Oklahoma City, Oklahoma, United States
Teva Investigational Site 10043
Philadelphia, Pennsylvania, United States
Teva Investigational Site 10003
Pittsburgh, Pennsylvania, United States
Teva Investigational Site 10049
Bluffton, South Carolina, United States
Teva Investigational Site 10037
Columbia, South Carolina, United States
Teva Investigational Site 10035
Greenville, South Carolina, United States
Teva Investigational Site 10047
Mt. Pleasant, South Carolina, United States
Teva Investigational Site 10016
Jackson, Tennessee, United States
Teva Investigational Site 10045
Knoxville, Tennessee, United States
Teva Investigational Site 10005
Memphis, Tennessee, United States
Teva Investigational Site 10042
Nashville, Tennessee, United States
Teva Investigational Site 10054
Dallas, Texas, United States
Teva Investigational Site 10019
Houston, Texas, United States
Teva Investigational Site 10020
San Antonio, Texas, United States
Teva Investigational Site 10038
Arlington, Virginia, United States
Teva Investigational Site 10024
Norfolk, Virginia, United States
Teva Investigational Site 10051
Norfolk, Virginia, United States
Teva Investigational Site 10053
Richmond, Virginia, United States
Teva Investigational Site 10027
Seattle, Washington, United States
Teva Investigational Site 10029
Tacoma, Washington, United States
Teva Investigational Site 80108
Beersheba, , Israel
Teva Investigational Site 80109
Giv‘atayim, , Israel
Teva Investigational Site 80104
Haifa, , Israel
Teva Investigational Site 80107
Haifa, , Israel
Teva Investigational Site 80101
Modiin, , Israel
Teva Investigational Site 80103
Or Yehuda, , Israel
Teva Investigational Site 80100
Petah Tikva, , Israel
Teva Investigational Site 80105
RishonLe'zio, , Israel
Teva Investigational Site 80102
Tel Aviv, , Israel
Teva Investigational Site 80106
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DSG-PPS-303
Identifier Type: -
Identifier Source: org_study_id